GB295656A - Process for the manufacture of difficultly soluble salts of organic bases and alkaloids - Google Patents

Process for the manufacture of difficultly soluble salts of organic bases and alkaloids

Info

Publication number
GB295656A
GB295656A GB23565/28A GB2356528A GB295656A GB 295656 A GB295656 A GB 295656A GB 23565/28 A GB23565/28 A GB 23565/28A GB 2356528 A GB2356528 A GB 2356528A GB 295656 A GB295656 A GB 295656A
Authority
GB
United Kingdom
Prior art keywords
acid
alkaloids
diethylaminoethyl
methoxy
aminoquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB23565/28A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IG Farbenindustrie AG
Original Assignee
IG Farbenindustrie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IG Farbenindustrie AG filed Critical IG Farbenindustrie AG
Publication of GB295656A publication Critical patent/GB295656A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

295,656. I. G. Farbenindustrie Akt.- Ges. Aug. 16, 1927, [Convention date]. Samples furnished. Salts of organic bases, including alkaloids.- Salts of alkaloids and of basic compounds obtainable according to Specifications 267,169, 274.058 and 286,087 are prepared by combining the base with a methylene compound of an aromatic carboxylic or sulphonic acid or by double decomposition in a solvent such as water of a salt of the base with a salt of the acid. The acid may contain hydroxy, amino, alkylamino or dialkylamino groups in the aromatic nuclei. The products, being tasteless, stable in the air, sparingly soluble in water, and readily decomposed by acids and alkalies into their components, are adapted for therapeutic use. Examples are given of salt formation between (1) 1-(N-methyl-diethylaminoethyl)-amino.-4-aminobenzene and methylene-disalicylic acid, and (2) methylene-di-#-hydroxynaphthoic acid and the following compounds:- N - ethyl - diethylaminoethylaniline, 1 : 2 - dimethoxy - 4-(N-di-diethylaminoethyl) - aminobenzene, 6 - methoxy-N-diethylaminoethyl-8-aminoquinoline, 6 - methoxy - N - (a - diethylamino-#- methylbutyl)-8-aminoquinoline. #-dithylamino- #<1> - (6 - methoxy-8-quinolyl)-aminogycol-diethylether, 6-methoxy-8-aminoquinoline, quinone and other cinchona, alkaloids and strychnine. N-Ethyl-diethylaminoethyl-aniline is prepared by interaction of ethylaniline and dietbylaminoethyl chloride.
GB23565/28A 1927-08-16 1928-08-15 Process for the manufacture of difficultly soluble salts of organic bases and alkaloids Expired GB295656A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE295656X 1927-08-16

Publications (1)

Publication Number Publication Date
GB295656A true GB295656A (en) 1929-11-15

Family

ID=6090116

Family Applications (1)

Application Number Title Priority Date Filing Date
GB23565/28A Expired GB295656A (en) 1927-08-16 1928-08-15 Process for the manufacture of difficultly soluble salts of organic bases and alkaloids

Country Status (1)

Country Link
GB (1) GB295656A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US8211905B1 (en) 2007-05-22 2012-07-03 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US8334322B1 (en) 2007-05-22 2012-12-18 Pisgah Laboratories, LLC Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8859622B1 (en) 2006-11-10 2014-10-14 Pisgah Laboratories, Inc. Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US8575151B1 (en) 2007-05-22 2013-11-05 Pisgah National Laboratories, Inc. Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US8334322B1 (en) 2007-05-22 2012-12-18 Pisgah Laboratories, LLC Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US8338444B1 (en) 2007-05-22 2012-12-25 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US8367693B1 (en) 2007-05-22 2013-02-05 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse anti-dose dumping properties
US8476291B1 (en) 2007-05-22 2013-07-02 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dumping properties
US8569329B1 (en) 2007-05-22 2013-10-29 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US8211905B1 (en) 2007-05-22 2012-07-03 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US8748416B1 (en) 2007-05-22 2014-06-10 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dumping properties
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US8921386B1 (en) 2007-05-22 2014-12-30 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products

Similar Documents

Publication Publication Date Title
GB295656A (en) Process for the manufacture of difficultly soluble salts of organic bases and alkaloids
US2688018A (en) Method of preparing alkaline earth metal salts of 1-leucovorin
Jones et al. THE BECKMANN REARRANGEMENT INVOLVING OPTICALLY ACTIVE RADICALS1
US3819689A (en) Resolution of dl-camphor-10-sulfonic acid
US2409001A (en) Esters of dimethylaminoethanol useful as local anesthetics
DE839500C (en) Process for the preparation of nitrophenylserines
US2580195A (en) Method of purifying 4-aminosalicylic acid
KIDD Mechanism of the diazoaminobenzene conversion
Paquette α-Halosulfones. III. The Steric Course of the Cycloaddition of Chlorosulfene to Enamines1
Hellerman et al. THE THERMAL DECOMPOSITION OF NITRITES. THE NITRITES OF TRIPHENYLETHYLAMINE AND DIPHENYLETHYLAMINE1
US2744931A (en) Anhydrochlortetracycline
Adams et al. Structure of Monocrotaline. IX. Proof of the Position of the Double Bond in Retronecine1
US2182075A (en) Water soluble derivatives of p-aminobenzenesulphonamide
GB501232A (en) New therapeutically active organic antimony compounds and the process for their manufacture
Ishidate et al. The Cleavage of Camphor Ring. V. 7-Hydroxy-π-apocamphane and 1-Hydroxy-10-apocamphor.
US3102883A (en) Morpholine acetic acid ester of chloramphenicol
US2614104A (en) Derivatives of para-amino salicylic acid
Hirschy et al. POLAROGRAPHIC DETERMINATION OF CITRININ1
US1892019A (en) osi basel
US2300677A (en) Nu-(1-carboxy-1-acylaminoethyl thiomethyl) and n, n&#39;-bis-(1-carboxy-1-acylaminoethylthiomethyl) derivatives of 4, 4&#39;-diaminodiphenyl sulphone, their salts, and the method of producing them and their salts
US2721198A (en) Amine salts of penicillin
Doak et al. The Preparation of Phenylarsenoxides. II. Derivatives of Amino-and Hydroxyphenylarsenoxides
Dyson Organic antimonials of therapeutic activity
Adams et al. Sulfanilamide Derivatives. II
US1670740A (en) Manufacture of aldehyde compounds of diamino-acridines and the novel product resulting therefrom